OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Endocrinology & Metabolism is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Myeloma and marrow adiposity: Unanswered questions and future directions	96
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	94
Editorial Board	92
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	91
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	65
Editorial Board	64
Editorial Board	59
Menopausal hormone therapy for the management of osteoporosis	52
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	52
Genetics of pubertal timing	47
Coronavirus disease 2019 and vitamin D	46
Regulation of bone mass: A splendid Orchestra	46
Gut microbiota and their metabolites in cardiovascular disease	45
Immune checkpoint inhibitor-related thyroid dysfunction	42
Sexual health and contraception in the menopause journey	41
Editorial Board	39
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	37
The role of androgens in transgender medicine	36
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	35
Prenatal exposure to phthalate esters and its impact on child development	34
Remnant lipoprotein particles and cardiovascular disease risk	34
Editorial Board	34
Haematological actions of androgens	33
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	33
Type 1 diabetes related to immune checkpoint inhibitors	31

Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	29
The effect of osteoporosis treatment on bone mass	29
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	29
Medullary thyroid cancer - An update	27
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	27
Endocrine-disrupting chemicals and behaviour: A high risk to take?	27
Non-oestrogen-based and complementary therapies for menopause	26
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	25
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	24
Metabolic complications and their mechanisms in patients with craniopharyngioma	24
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment	24
Radioiodine therapy in the different stages of differentiated thyroid cancer	23
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	22
Hormone therapy for menopause and premature ovarian insufficiency	22
Immune checkpoint inhibitor-related hypophysitis	21
Approach to patients with elevated low-density lipoprotein cholesterol levels	21
Pathophysiology of thyroid-associated orbitopathy	21
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	20
Editorial Board	20
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	20
Safety of androgen therapy in men with prostate cancer	20
Localization in primary hyperparathyroidism	20
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	20
History of androgens and androgen action	19
Gut microbiome and bile acids in obesity-related diseases	19
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	19
Editorial Board	19
Editorial Board	19
The role of hormone therapy in urogenital health after menopause	19
Genotype-phenotype correlations in Graves’ disease	19
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	18
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Genetics of anti-Müllerian hormone and its signaling pathway	18
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	17
Preface	17
Anaplastic thyroid cancer: An update	17
Endocrine disrupting chemicals and bone	17
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	17
Paraneoplastic autoimmune hypophysitis: An emerging concept	16
Chemokines in thyroid autoimmunity	16
COVID-induced thyroid autoimmunity	16
Exercise and physical activity in individuals at risk of fracture	16
Editorial Board	15
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	15
Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	15
Preface	15
Preclinical models for investigating how bone marrow adipocytes influence bone and hematopoietic cellularity	15
The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	15
The epidemiology of disorders of sex development	15
Covid-19 and endocrinology	15

Gut microbiome, prebiotics, intestinal permeability and diabetes complications